Anthera Pharmaceuticals, Inc. (ANTH) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 14, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerAnthera Pharmaceuticals, Inc. (ANTH) trades at $0.0001. Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing therapies for unmet medical needs. Sector: Healthcare.
Price as of · Last analyzed: Jun 14, 2026Analyst Coverage for ANTH: ANTH does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
Anthera Pharmaceuticals, Inc. (ANTH) Healthcare & Pipeline Overview
Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing therapies for unmet medical needs. With Sollpura in Phase III for exocrine pancreatic insufficiency and Blisibimod in Phase II for B-cell mediated autoimmune diseases, the company aims to address specific therapeutic gaps, operating within the specialized biotechnology sector from its Houston headquarters.
What Is the Investment Thesis for ANTH?
Anthera Pharmaceuticals, Inc. is positioned as a development-stage biopharmaceutical company with a pipeline focused on addressing unmet medical needs. The investment thesis centers on the potential for its lead investigational therapies, Sollpura and Blisibimod, to successfully navigate clinical trials and achieve regulatory approval. Sollpura, currently in Phase III for exocrine pancreatic insufficiency, represents a significant value driver; successful completion of this pivotal trial and subsequent commercialization could unlock substantial market potential, particularly given its non-porcine formulation as a differentiator. Blisibimod, in Phase II for B-cell mediated autoimmune diseases like IgA nephropathy, offers further upside if it demonstrates efficacy and safety in later-stage trials. The company's existing license agreements with Amgen, Inc., and Eli Lilly and Company also provide a foundation for potential future collaborations or revenue streams. However, the company's extremely small market capitalization of $0.00B, its OTC Other tier listing, and the inherent high-risk nature of clinical-stage biotechnology development, including potential trial failures, regulatory setbacks, and funding challenges, represent significant risk factors that must be carefully considered by investors.
Based on FMP financials and quantitative analysis
ANTH Key Highlights
Market Capitalization: $0.00B, indicating an extremely small valuation.
- Beta: -123.12, suggesting an inverse and highly volatile relationship with the broader market, which is atypical and warrants close scrutiny.
- Employee Count: Operates with a lean team of 21 employees, reflecting its development-stage focus.
- Dividend Policy: Does not currently pay a dividend, consistent with a growth-oriented, pre-revenue biopharmaceutical company.
- Clinical Pipeline Progress: Sollpura is in Phase III for exocrine pancreatic insufficiency, while Blisibimod is in Phase II for B-cell mediated autoimmune diseases.
Who Are ANTH's Competitors?
ANTH is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| ICCC ImmuCell Corporation | $9.75 | 0.00% | $88.2M | 77 5-pillar |
| RLYB Rallybio Corporation | $16.90 | -1.05% | $90.6M | 83 5-pillar |
| ORMP Oramed Pharmaceuticals Inc. | $4.55 | +1.34% | $184M | 76 5-pillar |
| ANTX AN2 Therapeutics, Inc. | $5.61 | -1.75% | $206M | 67 5-pillar |
| PLX Protalix BioTherapeutics, Inc. | $2.71 | 0.00% | $218M | 73 5-pillar |
| NAGE Niagen Bioscience Inc | $2.68 | -3.94% | $222M | 68 5-pillar |
| QTTB Q32 Bio Inc. | $8.37 | +1.70% | $245M | 67 5-pillar |
| CRMD CorMedix Inc. | $7.26 | +0.97% | $571M | 94 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are ANTH's Key Strengths?
Advanced clinical pipeline with Sollpura in Phase III and Blisibimod in Phase II, targeting significant unmet medical needs.
- Sollpura's non-porcine formulation offers a potential differentiator in the pancreatic enzyme replacement therapy market.
- Strategic license agreements with established pharmaceutical companies, Amgen and Eli Lilly, provide external validation and potential resource access.
- Focused R&D approach on specific therapeutic areas, allowing for specialized expertise.
What Are ANTH's Weaknesses?
Extremely small market capitalization ($0.00B) and low stock price ($0.0001), indicating significant financial distress.
- OTC Other tier listing, which typically implies lower transparency, liquidity, and increased risk for investors.
- High beta (-123.12) suggests extreme volatility and an unusual inverse correlation, indicating unpredictable price movements.
- Limited operational scale with only 21 employees, potentially straining resources for multiple advanced clinical programs.
What Are the Key Risks for ANTH?
Weak fundamentals — a Piotroski F-Score of 0/9 flags soft profitability, leverage or efficiency.
- **Ongoing:** Significant financial distress, evidenced by an extremely small market capitalization and low stock price, posing a risk of delisting or business cessation.
- **Potential:** Failure of Sollpura's Phase III clinical trial, which would severely impact the company's lead asset and future prospects.
- **Potential:** Inability to secure additional funding required to complete ongoing clinical trials or commercialize approved therapies.
- **Ongoing:** High regulatory risk inherent in biopharmaceutical development, including potential delays or outright rejection of drug candidates.
- **Potential:** Intense competition from larger, better-funded pharmaceutical companies developing similar or alternative treatments.
What Are ANTH's Competitive Advantages?
- **Proprietary Drug Candidates:** Development of unique investigational therapies like Sollpura (non-porcine PERT) and Blisibimod (B-cell modulator) in specific therapeutic areas.
- **Clinical Trial Progress:** Advancement of Sollpura to Phase III and Blisibimod to Phase II represents significant investment and progress, creating a lead time advantage over potential new entrants.
- **Targeted Unmet Needs:** Focus on specific diseases with high unmet medical needs, potentially leading to faster regulatory pathways and strong market positioning upon approval.
- **Strategic License Agreements:** Existing partnerships with established pharmaceutical companies like Amgen and Eli Lilly provide validation and potential access to resources or market reach.
What Does ANTH Do?
Anthera Pharmaceuticals, Inc., founded in 2004 and based in Houston, Texas, operates as a biopharmaceutical company dedicated to the development and commercialization of innovative medicines targeting patients with significant unmet medical needs. The company's strategic focus is on advancing its pipeline through clinical trials to bring novel therapies to market. A cornerstone of its development efforts is Sollpura, an investigational non-porcine pancreatic enzyme replacement therapy. This candidate is currently undergoing Phase III clinical trials, aiming to provide a new treatment option for individuals suffering from exocrine pancreatic insufficiency (EPI), a condition characterized by the inability to properly digest food due to a lack of digestive enzymes produced by the pancreas. The successful development and approval of Sollpura could address a critical demand within the gastroenterology therapeutic area, offering an alternative to existing porcine-derived enzyme therapies. In addition to Sollpura, Anthera Pharmaceuticals is also progressing Blisibimod, a drug candidate in Phase II clinical trials. Blisibimod is being developed for the treatment of B-cell mediated autoimmune diseases, specifically including immunoglobulin A nephropathy (IgA nephropathy). IgA nephropathy is a chronic kidney disease that occurs when immunoglobulin A (IgA) deposits build up in the kidneys, leading to inflammation and damage. The development of Blisibimod signifies the company's commitment to addressing complex autoimmune conditions where current treatment options may be limited or insufficient. The company's operational model is further bolstered by strategic license agreements with established pharmaceutical giants, Amgen, Inc., and Eli Lilly and Company. These agreements underscore Anthera's collaborative approach to drug development and potentially provide access to broader resources or expertise. Despite its small operational footprint, with 21 employees, Anthera Pharmaceuticals positions itself within the highly specialized biotechnology sector, aiming to carve out market niches by focusing on therapies for specific, often rare, diseases. The company's current market capitalization is noted as extremely small, and it trades on the OTC Other tier, indicating a focus on early-stage development and the inherent risks associated with biopharmaceutical ventures.
What Products and Services Does ANTH Offer?
- Develops Sollpura, a non-porcine pancreatic enzyme replacement therapy.
- Sollpura is in Phase III clinical trials for exocrine pancreatic insufficiency (EPI).
- Develops Blisibimod, a treatment for B-cell mediated autoimmune diseases.
- Blisibimod is in Phase II clinical trials for conditions like IgA nephropathy.
- Focuses on medicines for patients with unmet medical needs.
- Engages in license agreements with larger pharmaceutical companies like Amgen, Inc., and Eli Lilly and Company.
- Conducts biopharmaceutical research and development from its Houston, Texas headquarters.
How Does ANTH Make Money?
- **Research and Development:** Invests in preclinical and clinical studies to advance drug candidates through various development phases.
- **Clinical Trials:** Conducts rigorous human trials (Phase I, II, III) to prove the safety and efficacy of its investigational therapies.
- **Licensing and Partnerships:** Secures and maintains license agreements with larger pharmaceutical companies, potentially generating milestone payments or royalties.
- **Future Commercialization:** Aims to commercialize approved therapies, either independently or through partnerships, to generate product sales revenue.
What Industry Does ANTH Operate In?
Anthera Pharmaceuticals, Inc. operates within the highly specialized and research-intensive biotechnology industry, a sub-sector of healthcare. This industry is characterized by long development cycles, significant R&D investment, and high regulatory hurdles, but also offers substantial rewards for successful drug innovation, particularly in areas of unmet medical need. The market trend favors companies developing targeted therapies for specific diseases, especially those with orphan drug potential or significant patient populations lacking effective treatments. Anthera's focus on exocrine pancreatic insufficiency with Sollpura and B-cell mediated autoimmune diseases like IgA nephropathy with Blisibimod positions it within these niche, yet critical, therapeutic areas. The competitive landscape includes both large pharmaceutical companies with extensive R&D budgets and smaller, agile biotechs vying for market share in specific disease indications. Anthera's strategy appears to be one of differentiation through novel mechanisms or formulations, such as Sollpura's non-porcine nature, aiming to address specific patient needs not fully met by existing therapies.
Who Are ANTH's Key Customers?
- **Patients with Exocrine Pancreatic Insufficiency (EPI):** Individuals requiring enzyme replacement therapy, particularly those who might benefit from a non-porcine option.
- **Patients with B-cell Mediated Autoimmune Diseases:** Specifically, those diagnosed with conditions like IgA nephropathy, seeking novel treatment options.
- **Healthcare Providers:** Physicians, specialists, and hospitals who would prescribe or administer Anthera's approved therapies.
- **Pharmaceutical Partners:** Companies like Amgen and Eli Lilly, through strategic collaborations and licensing.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Insider Activity
12 transactions · 1 purchases, 0 sales, 11 other transactions · 9 identified insiders · most recent available transactions. Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Financial Health
Anthera Pharmaceuticals, Inc.'s Piotroski F-Score is 0/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
Earnings Track Record
Anthera Pharmaceuticals, Inc. has beaten Wall Street's EPS estimate in 4 of its last 8 reported quarters — more hits than misses. Reported results have landed about 4.6% below estimates on average.
Company Profile
Anthera Pharmaceuticals, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Houston, US. The company is led by CEO Paul F. Truex. ANTH has traded publicly since 2010.
ANTH Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
ANTH Latest News
-
Mistral bags $24 billion valuation as Samsung leads funding for Europe's AI champion
CNBC · Sep 8, 2026
-
Stocks That Hit 52-Week Lows On Tuesday
· Mar 24, 2020
-
Stocks That Hit 52-Week Highs On Tuesday
· Mar 24, 2020
-
Stocks That Hit 52-Week Lows On Friday
· Dec 13, 2019
ANTH Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for ANTH.
Price Targets
Wall Street price target analysis for ANTH.
ANTH MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for ANTH; grades run from A+ (80-100) to F (below 30).
Leadership: Paul F. Truex
Chief Executive Officer
Paul F. Truex serves as the Chief Executive Officer of Anthera Pharmaceuticals, Inc., leading a team of 21 employees in the company's mission to develop and commercialize medicines for unmet medical needs. His career trajectory in the biopharmaceutical sector has focused on guiding companies through critical stages of drug development and corporate strategy. Prior to his current role, Truex has accumulated extensive experience in executive leadership positions within the biotechnology industry, often at companies engaged in clinical-stage asset development. His background typically involves navigating the complexities of regulatory pathways, securing funding for R&D, and fostering strategic partnerships essential for advancing novel therapies from concept to market.
Track Record: Under Paul F. Truex's leadership, Anthera Pharmaceuticals has advanced Sollpura into Phase III clinical trials for exocrine pancreatic insufficiency, a significant milestone for a development-stage company. He has also overseen the progression of Blisibimod into Phase II trials for B-cell mediated autoimmune diseases. His tenure includes the establishment and maintenance of license agreements with major pharmaceutical entities, Amgen, Inc., and Eli Lilly and Company, which are crucial for a company of Anthera's size. These strategic decisions reflect a focus on pipeline development and leveraging external collaborations to enhance the company's prospects in a competitive industry.
ANTH OTC Market Information
Anthera Pharmaceuticals, Inc. trades on the OTC Other tier, which is the lowest and most speculative tier of the OTC Markets Group. Unlike companies listed on major exchanges such as the NYSE or NASDAQ, which have stringent listing requirements regarding financial health, market capitalization, and disclosure, companies on the OTC Other tier face minimal to no reporting standards. This tier is typically home to shell companies, defunct companies, or those with severe financial distress, often with little to no public information available. Investors in OTC Other securities face significantly higher risks due to the lack of transparency and regulatory oversight compared to higher OTC tiers or national exchanges.
- OTC Tier: OTC Other
- **Lack of Transparency:** Unknown disclosure status means limited access to financial statements and operational updates, hindering informed decision-making.
- **High Volatility and Price Manipulation:** Low trading volume and minimal oversight make the stock highly susceptible to extreme price fluctuations and potential manipulation.
- **Difficulty in Valuation:** Without reliable financial data and an an active market, accurately valuing the company's shares becomes exceptionally challenging.
- **Risk of Delisting/Cessation of Trading:** Companies on the OTC Other tier are at a higher risk of being delisted or having their trading suspended due to non-compliance or business failure.
- **Limited Investor Protections:** Regulatory protections are significantly weaker for OTC-traded securities compared to those on major exchanges.
- Verify the company's current operational status and any recent business activities.
- Attempt to locate any available financial statements or corporate filings, even if not formally disclosed.
- Research the background and track record of management beyond provided details.
- Assess the viability of its drug pipeline and the competitive landscape for its target indications.
- Understand the current share structure, outstanding shares, and any potential for dilution.
- Investigate any news or regulatory actions related to the company's OTC listing status.
- Consult with a financial advisor experienced in microcap and OTC markets.
- Clearly stated headquarters in Houston, US, and founding year of 2004.
- Identified CEO, Paul F. Truex, with a specified role and employee count.
- Specific drug candidates (Sollpura, Blisibimod) with stated clinical trial phases (Phase III, Phase II).
- Existence of license agreements with reputable pharmaceutical companies (Amgen, Eli Lilly).
- Focus on a legitimate and critical sector (Biotechnology) addressing unmet medical needs.
What Investors Ask About Anthera Pharmaceuticals, Inc. (ANTH) — Healthcare
What are the main risks for ANTH?
Anthera Pharmaceuticals, Inc. faces several significant risks. Foremost is the inherent financial distress, indicated by its extremely small market capitalization and low stock price, which raises concerns about its long-term viability and the potential for delisting from the OTC market.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Specific terms of license agreements with Amgen and Eli Lilly were not detailed in the source data.
- The "Unknown" disclosure status for OTC trading limits comprehensive due diligence.